Bittensor released Runtime 475, introducing Null Consensus, which allows subnet owners to increase registration capacity up to 2,500 identifiers, compared to the previous 256 limit under Yuma. This update centralizes miner scoring authority to the highest-stake-weight validator, bypassing previous consensus and bond calculations. The change enables more participants while maintaining dividend eligibility for all stakers. Additionally, proof-of-work registration is now optional, reducing registration costs for subnet owners.
Bittensor's new Runtime 475 update expands subnet capacity to 2,500 identifiers. For readers following the broader crypto market, here is Pluang's snapshot as of Oct 20, 2026 04:42 WIB: 46 of 50 major cryptocurrencies rose today. ATOM rose 7.33% to Rp31.274, EGLD gained 6.13% to Rp64.853, and UNI increased 5.66% to Rp130.220, with typical hold times ranging from 61 to 86 days.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...
Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...
